These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37768671)

  • 1. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
    Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
    JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
    Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
    Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
    Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
    J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.
    Yarlas A; Lovley A; Brown D; Kosinski M; Vera-Llonch M
    J Neurol; 2022 Jan; 269(1):323-335. PubMed ID: 34125267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
    Conceição I; Berk JL; Weiler M; Kowacs PA; Dasgupta NR; Khella S; Chao CC; Attarian S; Kwoh TJ; Jung SW; Chen J; Viney NJ; Yu RZ; Gertz M; Masri A; Cruz MW; Coelho T
    J Neurol; 2024 Aug; ():. PubMed ID: 39138650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
    Masri A; Maurer MS; Claggett BL; Kulac I; Waddington Cruz M; Conceição I; Weiler M; Berk JL; Gertz M; Gillmore JD; Rush S; Chen J; Zhou W; Kwoh J; Duran JM; Tsimikas S; Solomon SD
    J Card Fail; 2024 Aug; 30(8):973-980. PubMed ID: 38065307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
    Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
    Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
    Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
    Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment for familial amyloid polyneuropathy.
    Magrinelli F; Fabrizi GM; Santoro L; Manganelli F; Zanette G; Cavallaro T; Tamburin S
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012395. PubMed ID: 32311072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
    Coelho T; Yarlas A; Waddington-Cruz M; White MK; Sikora Kessler A; Lovley A; Pollock M; Guthrie S; Ackermann EJ; Hughes SG; Karam C; Khella S; Gertz M; Merlini G; Obici L; Schmidt HH; Polydefkis M; Dyck PJB; Brannagan Iii TH; Conceição I; Benson MD; Berk JL
    J Neurol; 2020 Apr; 267(4):1070-1079. PubMed ID: 31853709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
    Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
    Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen.
    Karam C; Brown D; Yang M; Done N; Dieye I; Bozas A; Vera Llonch M; Signorovitch J
    Muscle Nerve; 2022 Sep; 66(3):319-328. PubMed ID: 35766224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
    Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
    Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Olatunji G; Kokori E; Abraham IC; Omoworare O; Olatunji D; Ezeano C; Emmanuel Adeoba B; Stanley AC; Oluwatobiloba AM; Oluwademilade OB; Shimelis KM; Olanisa O; Aderinto N
    Medicine (Baltimore); 2024 Jun; 103(26):e38767. PubMed ID: 38941378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplontersen: First Approval.
    Nie T
    Drugs; 2024 Apr; 84(4):473-478. PubMed ID: 38413492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.